How a 510(k) Predicate Strategy Works: What Brands Should Understand Before the Conversation

RedVance manufactures red light therapy panels in Shenzhen. This guide is educational: it does not describe a 510(k) clearance held by RedVance, and predicate selection for any specific device is a regulatory determination that requires qualified professional guidance.

A 510(k) submission does not independently prove a new device is safe and effective from first principles. It argues that the device is substantially equivalent to an existing, legally marketed device — the predicate — and FDA’s clearance is a finding that the argument holds. This is a fundamentally comparative process rather than a standalone safety demonstration, which is why the predicate chosen is not a formality but the foundation the entire submission rests on.

FDA’s framework for substantial equivalence considers a specific list of factors: intended use, technological characteristics, design, energy used or delivered, materials, performance, safety, effectiveness, labeling, biocompatibility, and applicable standards.

Where technological characteristics differ from the predicate, the submission has to explain those differences and show they don’t raise new questions of safety or effectiveness. A device does not need to be identical to its predicate — FDA’s own guidance notes this is rarely the case — but differences have to be justified rather than simply present.

• Legally marketed. The predicate cannot be a device that is or was in violation of the Food, Drug and Cosmetic Act.
• Preamendment or postamendment. A predicate can technically be a device marketed before May 28, 1976, or one legally marketed after that date — but because device technology has moved on so substantially, almost all current submissions rely on a postamendment predicate, typically one cleared relatively recently.
• Not necessarily still on the market. A submission can claim equivalence to a device no longer actively sold, provided it was legally marketed.

A device that has been recalled or found to pose safety issues is a problematic predicate choice, and this is a documented concern in the regulatory literature, not a hypothetical one.

It’s possible to reference multiple predicates in a single submission — for example, where different predicates each support a different technological characteristic of a multi-function device. But FDA’s own guidance on predicate selection generally favours a clearly defined primary predicate, because an overly complex framework built on several predicates can dilute the substantial equivalence argument and make the logic harder for reviewers to follow.

The practical takeaway for a brand evaluating a submission strategy: a clean, well-matched single predicate is usually a stronger starting position than a patchwork of partial matches assembled to cover every feature.

The regulatory literature describes a phenomenon known as predicate creep: a device clears based on a predicate, a later device clears based on that device, and so on across successive rounds — with each individual step appearing reasonable, but the cumulative drift meaning the current device can differ substantially from the original predicate years earlier.

A brand planning a single SKU can treat predicate selection as a one-time decision. A brand planning a range — variations in size, an added feature, a different form factor down the line — benefits from thinking about predicate strategy across the range from the start, because:

• The intended use claimed for the first device constrains what can be claimed for variants without triggering a fresh assessment.
• A well-chosen initial predicate can make later related submissions more straightforward if the technological relationship is clear and well-documented.
• A poorly chosen or overly narrow predicate can create friction for every subsequent model, each requiring more justification than it might have with better initial planning.

This is the level at which serious OEM conversations in this category are increasingly happening — not “can you build this one panel” but “how does a clearance strategy support the next three models.” It connects to the broader claims discipline in our claims verification guide and the cleared-versus-registered distinction in our FDA 510(k) verification guide.

1. “What predicate options exist for this intended use, and why is one stronger than the alternatives?”
2. “Is this predicate still in good standing — not recalled, not subject to safety findings?”
3. “Are we relying on one clean predicate, or several — and if several, why?”
4. “How many steps of predicate creep sit behind this chain, and does the current device still resemble the original?”
5. “If we plan further models later, does this predicate choice support them, or box us in?”

These are the questions that separate a brand treating regulatory strategy as an afterthought from one planning it alongside the product itself.

1. Intended use for the new device clearly defined before predicate search begins.
2. Candidate predicates reviewed for legal marketing status and safety history.
3. Preference given to one clean predicate over a patchwork of several, where possible.
4. Predicate chain traced back where relevant, to check for meaningful drift from the original.
5. Range-level planning considered, not only the immediate submission.
6. A qualified regulatory professional engaged before predicate selection is finalised.

This is one of four expansion directions covered in our product expansion hub, and sits alongside our market-by-market regulatory hub.

What a manufacturer can usefully contribute to this conversation: accurate technical documentation of the device’s design, materials, energy delivery and performance characteristics — the raw material a regulatory consultant needs to evaluate predicate fit — rather than predicate selection itself, which is a regulatory determination outside a factory’s role. A supplier who understands this distinction and defers appropriately is more useful than one who implies they can shortcut the regulatory process.